Sophia Abene

The role of Anti-HDV IgG tests in diagnosing HDV in patients with Hepatitis B, showing sensitivity and specificity, making these serological tests important for identifying this form of viral hepatitis.

The study estimates that vaccination efforts may have averted between 610,000 and 2.61 million deaths during the first 18 months of the rollout.

Initial studies show its effectiveness against various bacteria, including those resistant to standard treatments, and it is being developed in both intravenous and oral forms to improve patient access.

Adults with type 2 diabetes taking metformin have a 13% to 21% lower risk of developing Long COVID or dying from COVID-19, recent analyses question the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new variants, and more this week from Contagion.

Over half of US infants are infected with respiratory syncytial virus (RSV) during infancy, with 2.8% requiring hospitalization.

Initial studies show its effectiveness against various bacteria, including those resistant to standard treatments, and it is being developed in both intravenous and oral forms to improve patient access.

Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.

By analyzing 38 strains from patients, researchers identified clusters linked to frequent room changes, highlighting the need for improved infection control measures.

The model predicts and stratifies hepatocellular carcinoma risk by analyzing serum HBV DNA levels and other factors to enhance early detection and management.

Adults with type 2 diabetes who use metformin have a 13% to 21% reduced risk of developing Long COVID or dying from COVID-19 compared to those taking other diabetes medications.

Uzma Syed, MD, DO discussed how various factors increase women’s susceptibility to AMR, the importance of policies, and the need for culturally specific education and advocacy to improve health outcomes.

With no vaccines or specific treatments available, the mosquito-borne pathogen, which causes fever, severe headache, and joint pain, raises alarms due to its spread across the Americas.

At the World AMR Congress, Yann Ferris discussed how leveraging partnerships enhances the fight against antimicrobial resistance.

Protein organization could pave the way for effective vaccine development

Females are more frequently affected by Long COVID than males, highlighting distinct immunological processes and hormonal variations.

The benefits, challenges, and prospects of wastewater data in enhancing public health strategies against AMR.

The study on the E coli outbreak in the UK highlights the growing impact of climate change on public health and food security.

The gene USP26 is identified as a factor in hepatocellular carcinoma development and a potential therapeutic target.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.

FDA announced the outbreak already impacted 65 people across 9 states, with 24 hospitalizations.

First case this year without a documented occupational exposure to infected animals.

James Graham, CEO discussed the company's progress in developing a new antibiotic for sepsis and diabetic foot ulcers.

Britton Strickland, MD discusses innovations in microbiome research and their impact on antimicrobial resistance.

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.

Akhila Kosaraju, MD, addresses overcoming key challenges in antibiotic development using AI, a nonprofit model, and supportive policies.

Insights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.

The Phase 1/2 study of VAX-31 demonstrated that the vaccine was well tolerated and elicited strong opsonophagocytic activity immune responses across all 31 evaluated serotypes.

Results in about 5.5 to 6 hours, employing advanced technology to detect bacterial growth and minimum inhibitory concentration.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.